Team
Continuous project advances will be possible thanks to the passion and drive of the ONESTX team members with experience in biotech companies, research, management and successful exit of investment:
Board of Directors
Ángel Cebolla
CEO
PhD. Pharmacist. CEO. Broad experience during 22 years as entrepreneur and founder of biotech companies. CEO of Biomedal SL, IVD company, forming multiple R&D teams, managing, and coordinating public-private research projects. He has more than a hundred publications and is co-inventor of fifteen patent applications. Biomedal has carried out one of the most successful operations in Spanish biotechnology with a self-developed product that has become the world leader in its category (Glutentox®), leading the exit of the business unit to an expanding North American company such as Hygiena. He is cofounder of several high tech companies that launched innovative products (Biomedal, Ingeniatrics, Glutenostics, etc).
Manuel Muñoz
Founder and CSO
PhD. Founder and CSO. Manuel has more than 30 years of research experience in genetics. His main research area is the genetic regulation of longevity. He has published in high impact journals in different fields. Deeply involved in technology transfer processes by developing new technologies for the industrial application. He is the author of seven patents (3 licensed), two industrial secrets and promoter of two biotechnology companies: CEPA S.L. and Olavide Neuron STX (ONESTX). Professor at University Pablo de Olavide.
Jorge Alemany
Founder
MD, PhD, MBA. Founder and non-executive director at ONESTX. Fifteen years of experience in research institutions such as NIH and management roles at CNIO Spain in the USA. Focused in translational research, he started to work in biotech industry as Director of PharmaGen (today Genomica SAU). Director of Innovation and Business Development at Genetrix. Jorge was Co-Director at Spherium Biomed and Biosurgery. Founder and CEO of Cellerix (later Tigenix), which after obtaining Marketing Authorization for the first ATMP on the market, was acquired in 2017 by Takeda Pharmaceuticals. He is currently the CEO of OneChain Immunotherapeuics, an immuno-oncology company focused on CAR-Ts.
Luis Ruiz-Ávila
Founder
PhD. Founder and non-executive director at ONESTX. Ten years of academic research in Spain (CSIC, UB) and US (Roche, Mount Sinai NY). His business career started at Almirall, in project management and business development. Founder and CEO of Advancell, one of the first biotechnological spin-offs in Spain. He has participated in the creation of ERA-Plantech (today ERA-Biotech), TCD-Pharma and Spherium Biomed, among others. Founding Partner of JANUS DEVELOPMENTS with the responsibility of transferring projects of academic origin to drug development stage for unsatisfied medical needs. In recent years, he has held executive positions in several biotech companies and helped with start companies in the academic spin-off space (Biosintaxis, Leukos Biotech, Affirma Bio). CEO at Aquilon CyL and Leukos Biotech.
Operations
Viñas Andrés Simón
Director, Clinical Operations and Development
Neuroscientist (PhD) with a broad experience in the basic, preclinical and clinical research. In charge of projects related to bioanalysis, biomarkers, neuroimaging, pharmacogenetic and -omics. Within the last 25 years she has performed different roles in the field of clinical research. Since 2006 to 2021, first in Biotech (Noscira) and later in large CRO (Syneos Health), she has been mainly involved in preclinical and clinical development projects in neurodegenerative diseases (Alzheimer, Parkinson and PSP). Former Director of Clinical Operations and Development at Peaches Biotech. She joins ONESTX to lead the drug development and clinical trial program.
Sandra Gavaldá
Project Manager
PhD, PMP. Project Manager. Researcher with a molecular biology background in public institutions and private companies. Leading R&D projects at bioethanol production industry and biomedicine (ATMPs) companies in the last 10 years. Coordinator of multidisciplinary teams in the tech transfer activities from bench to clinical phase at Ixaka (a Cell Therapy company).
Manuel Muñoz
Founder and CSO
PhD. Founder and CSO. Manuel has more than 30 years of research experience in genetics. His main research area is the genetic regulation of longevity. He has published in high impact journals in different fields. Deeply involved in technology transfer processes by developing new technologies for the industrial application. He is the author of seven patents (3 licensed), two industrial secrets and promoter of two biotechnology companies: CEPA S.L. and Olavide Neuron STX (ONESTX). Professor at University Pablo de Olavide.
Ángel Cebolla
CEO
PhD. Pharmacist. CEO. Broad experience during 22 years as entrepreneur and founder of biotech companies. CEO of Biomedal SL, IVD company, forming multiple R&D teams, managing, and coordinating public-private research projects. He has more than a hundred publications and is co-inventor of fifteen patent applications. Biomedal has carried out one of the most successful operations in Spanish biotechnology with a self-developed product that has become the world leader in its category (Glutentox®), leading the exit of the business unit to an expanding North American company such as Hygiena. He is cofounder of several high tech companies that launched innovative products (Biomedal, Ingeniatrics, Glutenostics, etc).
Mercedes Pérez-Jiménez
Founder and Aging processes advisor
PhD. Founder. Expert in biology and genetics of aging. International experience at CNRS, where she contributed to broadening scientific knowledge on germline development in nematodes. Her current line of research is the use of steroid sulfatase inhibition for the expansion of life span and to inactivate neurodegeneration in animal models. Co-inventor together with Manuel Muñoz and Ángel Carrión of patents that back the project. Associate researcher at University Pablo de Olavide.
Ángel Manuel Carrión
Founder and Mammal model advisor
PhD. Founder. In the last 22 years he applies a multidisciplinary approach to the fields of nociception and cognitive processes, from behavior to its molecular basis. He leads a pioneering research group in describing the role of steroid sulfatase inhibitors in neurodegenerative diseases, in addition to the role of aging in these pathologies. Professor at the Pablo de Olavide University.
